Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

Example Group: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer

Generated Narrative: Group 179619

version: 4; Last updated: 2023-12-06 00:11:33+0000

Profile: SystematicReviewEligibilityCriteria

Artifact related artifact: No display for RelatedArtifact (type: cite-as; citation: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer [Group]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179619. Revised 2023-12-04. Available at: https://fevir.net/resources/Group/179619. Computable resource at: https://fevir.net/resources/Group/179619.)

Artifact Author: Brian S. Alper:

url: https://fevir.net/resources/Group/179619

identifier: FEvIR Object Identifier/179619

name: SystematicReviewEligibilityCriteria_ADT_and_Docetaxel_vs_ADT_alone_for_metastatic_hormone_naive_prostate_cancer

title: SystematicReviewEligibilityCriteria: ADT and Docetaxel vs. ADT alone for metastatic hormone-naive prostate cancer

status: Active

publisher: Computable Publishing LLC

contact: support@computablepublishing.com

description:

Study selection criteria Types of Studies. Randomized controlled clinical trials (RCTs) with parallel design that compared the association of ADT and chemotherapy (docetaxel), versus ADT alone.

Types of participants. Patients aged ≥18 years with cytological or histological diagnosis of mHNPC.

UseContexts

-CodeValue[x]
*Evidence Based Medicine on FHIR Implementation Guide Code System evidence-communication: Evidence CommunicationSystematicReviewEligibilityCriteria

copyright:

https://creativecommons.org/licenses/by-nc-sa/4.0/

membership: Conceptual

combinationMethod: All of

characteristic

code: Study Design

value: randomized assignment

exclude: false

description:

Randomized controlled clinical trials (RCTs)

characteristic

code: Study Design

value: Parallel cohort design

exclude: false

description:

parallel design

characteristic

code: Comparison

value: GroupAssignment: ADT plus docetaxel vs. ADT alone

exclude: false

description:

compared the association of ADT and chemotherapy (docetaxel), versus ADT alone

characteristic

code: Age

value: >=18 years (Details: UCUM codea = 'a')

exclude: false

description:

Types of participants. Patients aged ≥18 years

method: applied to participants in the studies

characteristic

code: Disease (disorder)

value: metastatic hormone-naive prostate cancer

exclude: false

description:

Types of participants. Patients with cytological or histological diagnosis of mHNPC.

method: applied to participants in the studies, cytological or histological diagnosis